Interestingly, both mechanisms involved in MC‐SeC treatment are known to be very efficacious in DMD patients: the extinction of the inflammatory response and the induction of expression of the dystrophin paralogue, utrophin, at the sarcolemma. The gene discussed is UTRN; the disease is Duchenne muscular dystrophy.